Loading
A phase 1/2 trial of Alemtuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Cellectis S.A., now recruiting.
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05607420 by Cellectis S.A., with 80 participants planned, started 2022-11-01 and due to reach its primary completion in 2027-08. Interventions recorded: UCART20x22, CLLS52. Conditions listed: B-cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.